{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:05:35Z","timestamp":1790975135369,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":371,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Activation of B cells and T cells requires the engagement of costimulatory signaling pathways in addition to Ag receptor signaling for efficient immune responses. None of the typhoid Vi polysaccharide (ViPS) subunit vaccines contains adjuvants that could activate costimulatory signaling pathways, yet these vaccines are very immunogenic. I hypothesized that residual TLR ligands present in the ViPS preparation used for making typhoid subunit vaccines account for the robust immune response generated by these vaccines. I show the presence of endotoxin, a potent agonist of TLR4, in ViPS preparations and ViPS vaccines. Furthermore, I found that ViPS obtained from various sources induces the production of proinflammatory cytokines such as IL-6 from mouse peritoneal exudate cells. Unconjugated and tetanus toxoid\u2013conjugated ViPS vaccines activate human and mouse TLR4. Mice deficient in TLR4 or the signaling adaptors MyD88 and Trif (Toll\/IL-1R domain\u2013containing adapter inducing IFN-\u03b2) are severely impaired in generating anti-ViPS responses to these vaccines. Elimination of the TLR4 agonist in ViPS preparation resulted in the loss of immunogenicity, and addition of lipid A, a known TLR4 agonist, restored the immunogenicity. These data highlight the importance of associated TLR ligands in the immunogenicity of ViPS subunit vaccines.<\/jats:p>","DOI":"10.4049\/immunohorizons.2300085","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:57:43Z","timestamp":1704463063000},"page":"29-34","source":"Crossref","is-referenced-by-count":7,"title":["TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-514X","authenticated-orcid":false,"given":"Kishore R","family":"Alugupalli","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University , Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2025010608545609200_r1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/649541","article-title":"Global trends in typhoid and paratyphoid fever","volume":"50","author":"Crump","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"2025010608545609200_r2","doi-asserted-by":"crossref","first-page":"e0006779","DOI":"10.1371\/journal.pntd.0006779","article-title":"A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid","volume":"12","author":"Britto","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"2025010608545609200_r3","doi-asserted-by":"crossref","first-page":"S781","DOI":"10.1093\/infdis\/jiab449","article-title":"Typhoid conjugate vaccines: advancing the research and public health agendas","volume":"224","author":"Birkhold","year":"2021","journal-title":"J. Infect. Dis."},{"key":"2025010608545609200_r4","doi-asserted-by":"crossref","first-page":"e20201116","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"J. Exp. Med."},{"key":"2025010608545609200_r5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/B978-1-4160-3611-1.50038-6","volume-title":"Vaccines","author":"Levine","year":"2008","edition":"5th Ed"},{"key":"2025010608545609200_r6","doi-asserted-by":"crossref","first-page":"e60583","DOI":"10.1371\/journal.pone.0060583","article-title":"Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines\u2014a randomized trial","volume":"8","author":"Kantele","year":"2013","journal-title":"PLoS One"},{"key":"2025010608545609200_r7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00063030-200115001-00002","article-title":"Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration","volume":"15","author":"Lebacq","year":"2001","journal-title":"BioDrugs"},{"key":"2025010608545609200_r8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2025010608545609200_r9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"2025010608545609200_r10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"2025010608545609200_r11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12887-020-02375-4","article-title":"A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11\u2009years: a phase II preliminary report","volume":"20","author":"Medise","year":"2020","journal-title":"BMC Pediatr."},{"key":"2025010608545609200_r12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025010608545609200_r13","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"2025010608545609200_r14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"Lancet"},{"key":"2025010608545609200_r15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","volume":"54","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"2025010608545609200_r16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"2025010608545609200_r17","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"2025010608545609200_r18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/aem.36.3.445-449.1978","article-title":"Endotoxins in commercial vaccines","volume":"36","author":"Geier","year":"1978","journal-title":"Appl. Environ. Microbiol."},{"key":"2025010608545609200_r19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jps.22267","article-title":"Acceptable levels of endotoxin in vaccine formulations during preclinical research","volume":"100","author":"Brito","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"2025010608545609200_r20","first-page":"58","article-title":"Endotoxin content in Haemophilus influenzae type b vaccine","volume":"57","author":"Ochiai","year":"2004","journal-title":"Jpn. J. Infect. Dis."},{"key":"2025010608545609200_r21","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1016\/j.vaccine.2013.08.037","article-title":"A novel method for purification of Vi capsular polysaccharide produced by Salmonella enterica subspecies enterica serovar Typhi","volume":"31","author":"Kothari","year":"2013","journal-title":"Vaccine"},{"key":"2025010608545609200_r22","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.4049\/jimmunol.1701348","article-title":"An unmutated IgM response to the Vi polysaccharide of Salmonella Typhi contributes to protective immunity in a murine model of typhoid","volume":"200","author":"Pandya","year":"2018","journal-title":"J. Immunol."},{"key":"2025010608545609200_r23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4049\/jimmunol.165.2.618","article-title":"Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2","volume":"165","author":"Hirschfeld","year":"2000","journal-title":"J. Immunol."},{"key":"2025010608545609200_r24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1615\/CritRevImmunol.v31.i5.20","article-title":"LPS-induced cytokine production in human monocytes and macrophages","volume":"31","author":"Rossol","year":"2011","journal-title":"Crit. Rev. Immunol."},{"key":"2025010608545609200_r25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1086\/368200","article-title":"Immunogenic protein contaminants in pneumococcal vaccines","volume":"187","author":"Yu","year":"2003","journal-title":"J. Infect. Dis."},{"key":"2025010608545609200_r26","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.4049\/jimmunol.175.5.3084","article-title":"In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands","volume":"175","author":"Sen","year":"2005","journal-title":"J. Immunol."},{"key":"2025010608545609200_r27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/infdis\/jiy506","article-title":"An adjuvant that increases protective antibody responses to polysaccharide antigens and enables recall responses","volume":"219","author":"Phipps","year":"2019","journal-title":"J. Infect. Dis."}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/1\/29\/60188902\/ih2300085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/8\/1\/29\/60188902\/ih2300085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:55:31Z","timestamp":1736153731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/8\/1\/29\/7817015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.2300085","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]}}}